gci

Current Issue cover

BASF x Caregen Deal on Synthetic Peptide Portfolio

Contact Author
Close
Fill out my online form.

BASF signs an executive supply agreement with Caregen for synthetic peptides, expanding BASF’s dermocosmetics portfolio and offering more cosmetic solutions.

 

BASF has signed a global, exclusive supply agreement with Caregen. With this expansion of BASF’s portfolio, the company plans to launch four peptides with anti-aging and anti-pigmentation properties for atopic- and acne-prone skin.

Related: BASF Increases Prices for Select Polyetheramines in U.S., Canada

Caregen’s synthetic peptides will be complementary to the bioactive, cosmetic solutions and ingredients offered by BASF’s personal care portfolio.

“There is robust growth in the dermocosmetics sector globally and especially in Asia as more consumers desire targeted functionality from cosmetics, in line with the personalization trend,” said Jeff Huh, head of marketing personal care solutions at BASF Asia Pacific. “By using cosmetic products formulated with these peptides as active ingredients, consumers can have a choice of products with proven efficacy.”

“Peptides are widely used as biological actives in different markets,” said David Hérault, head of global product development bio-actives at BASF Care Chemicals. “Selecting the most promising peptides from Caregen’s portfolio and adapting them to the standards of the cosmetic industry has been a great achievement of our team.”

“Building on Caregen’s functional peptides with technical and commercial competitiveness, and BASF’s expertise in solutions and ingredients, which are offered to the global cosmetic market, this agreement has both companies set up for a long-term cooperation,” said Chung Yong-Ji, Ph.D., CEO of Caregen. “With the ongoing functional health, food and pharmaceutical product development, Caregen aims to soon become a leading peptide platform company, recognized by global customers.” 

For more information, contact BASF.